Overview

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Status:
Completed
Trial end date:
2020-02-10
Target enrollment:
Participant gender:
Summary
This study will evaluate the recommended Phase 2 combination dose (RP2D) of eribulin with durvalumab.
Phase:
Phase 1
Details
Lead Sponsor:
Amy Tiersten
Collaborators:
AstraZeneca
Eisai Inc.
Treatments:
Antibodies, Monoclonal
Atezolizumab
Durvalumab